MEACB 2017
8th Meeting of the European Advisory Committees on Biosafety
in the field of contained use and deliberate release of GMOs
23-24 November 2017, Liège, Belgium

Scientific Programme

Thursday, 23th November 2017

10:15	Welcome (Dr. D. Breyer, Head *a.i.* SBB)	
10:30	**SESSION I : Evidence-based risk management**	
	Prof. P. Van Damme (University of Antwerp, Belgium)	The conduct of a vaccine study with a novel live attenuated polio vaccine, under containment.
	Dr. N. Willemarck (Scientific Institute of Public Health, Belgium)	Evidence-based biosafety.
	Dr. S. Strassheim (ZKBS, Germany)	Environmental risk assessment of GMO medicinal products – New procedures, new challenges?
	Session discussion	
12:30	Lunch	
14:00	**SESSION II: High-throughput technologies for molecular characterization and risk assessment of GMOs**	
	Dr. H. Schouten (Wageningen University and Research, The Netherlands)	How mutagenic is *Agrobacterium tumefaciens*-mediated transformation? Whole genome sequencing of transgenic plants.
	Dr. E. Van Leeuwe-Kok (RIKILT, The Netherlands)	How to assess the safety of new plant varieties in the years to come?
	Session discussion	
15:30	Coffee break	
15:45	**SESSION III: Novel developments in GM plants**	
	Dr. Ir. O. Christiaens (Ghent University, Belgium)	RNAi-based GM crops: Biosafety and risk assessment considerations.
	Prof. W. Wackernagel (ZKBS, Germany)	ZKBS assessment of two genome edited plants for intended deliberate release in Germany.
	Session discussion	
17:00	**Round table discussion "Challenges for risk assessment/regulation of GMOs"**	
	Open discussion introduced by short communications from Dr. K. Pauwels (Scientific Institute of Public Health, Belgium) and Dr. C. van der Vlugt-Bergmans (RIVM, The Netherlands).	
18:00	END DAY 1	
19:30	SOCIAL EVENT: Dinner – Restaurant "Le Labo 4"	

Friday, 24th November 2017

9:00	**SESSION IV : GMO medicinal products for human or veterinary use**	
	Dr. M. Ramon (EFSA, Italy)	Plasmid vaccines: considerations on the integration potential into the genome and on the risk assessment of non-heritable traits.
	Dr. F. Lim (Universidad Autonoma de Madrid, Spain)	Risk considerations of the growing biomedical use of herpesvirus vectors.
	Dr. G.P. Pijlman (Wageningen University, The Netherlands)	Environmental safety of synthetic replicon particle vaccines – risk for RNA recombination with wildtype viruses (RepliSAFE).
	Session discussion	
11:00	Coffee break	
11:30	**SESSION V: Increasing dissemination and use of scientific contributions on GM risk assessment**	
	Dr. C. Kohl (Julius Kühn-Institut, Germany)	CADIMA: An open-access online tool and database increasing the transparency and traceability of (GMO) impact data.
	Dr. I. Munoz Guajardo (EFSA, Italy)	Explanatory note on literature searching conducted in the context of GMO applications.
	Session discussion	
12:45	Lunch	
14:00	**Session VI: Biosafety by design**	
	Dr. C. van der Vlugt (RIVM, The Netherlands)	Risk Assessment and Management of Gene Drive Technology.
	Dr. M. Renders (KULeuven, Belgium)	Biosafety: what Xenobiology has to offer.
	Session discussion	
15:15	**KEYNOTE LECTURE**	
	Dr. B. Glandorf (RIVM, The Netherlands)	Environmental risk assessment of a potential release of GM mosquitoes on the island of Saba.
16:15	Concluding remarks	
16:30	CLOSURE OF THE MEETING	